Nucana is a clinical-stage biopharmaceutical company developing cancer therapeutics based on phosphoramidate chemistry, converting nucleoside analogs into activated nucleotide analogs, including the clinical candidate NUC-7738.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Phase 2 · ActiveModality: small molecule (ProTide)
Target nucleotide metabolism (ProTide prodrug)
Partnerships License and collaboration agreement with Cardiff ProTides Ltd. (core IP for ProTide platform).
Indications
Advanced solid tumors (monotherapy)(Phase 2)
Melanoma (in combination with pembrolizumab)(Phase 2)
Status note ProTide candidate in the Phase 2 part of the NuTide:701 Phase 1/2 trial in patients with advanced solid tumors, evaluated as monotherapy and in combination with pembrolizumab in melanoma. The company depends heavily on the success of NUC-7738 and NUC-3373.
NUC-3373
Phase 1 · ActiveModality: small molecule (ProTide)
Target nucleotide metabolism (ProTide prodrug)
Indications
Advanced solid tumors (in combination with pembrolizumab)(Phase 1)
Lung cancer (in combination with docetaxel)(Phase 1)
Status note ProTide candidate recently evaluated in the Phase 1b/2 modular NuTide:303 trial in combination with pembrolizumab for advanced solid tumors and with docetaxel for lung cancer; company evaluating optimal combinations and indications for further trials. The company depends heavily on the success of NUC-3373 and NUC-7738.
Per-asset detail extracted from the 20-F filed 2026-03-19. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.